Business
Thomas McLain Appointed as President and CCO
Thomas McLain Appointed as President and CCO.
About this update from Renalytix Plc
[{"type":"text","content":"\n \nRNS Number : 9424G Renalytix AI PLC 29 July 2019 \n\nRenalytix AI plc\n(\"RenalytixAI\" or the \"Company\")\n \nThomas McLain Appointed as President and Chief Commercial Officer\n \nRenalytixAI Expands Leadership Team with Focus on Reimbursement ahead of roll-out of artificial intelligence clinical in vitro diagnostic KidneyIntelX ™ \n \nRenalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, announces the expansion of its leadership team with the appointment of diagnostic industry leader Thomas McLain as President and Chief Commercial Officer, effective immediately. In this non-Board role, McLain will be responsible for leading the commercial programme for KidneyIntelX ™ with a focus on establishing national and international clinical adoption and reimbursement. \n \nMcLain most recently led business and commercial strategy for the Exosome Diagnostics' ExosomeDx® Prostate (Intelliscore) (\"EPI\") test, a liquid biopsy diagnostic for identifying men at increased risk for aggressive or high grade prostate cancer. While at Exosome Diagnostics, McLain secured a series of milestones for EPI within the first 18 months of national launch including a CPT code, Medicare pricing of $760 per test, private payer coverage determinations for more than 200 million lives in the US, inclusion in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines, and a recent grant of FDA Breakthrough Device Designation. \n \nMcLain has been recognised as a leading voice for progressive diagnostic reimbursement strategy including innovative collaborations and programmes with private insurance groups to stimulate utility, outcome and health economic data collection leading to accelerated clinical adoption and positive coverage determinations. \n \nMcLain has served as President, Chief Executive Officer (CEO), General Manager, Board Chair and Board member of numerous successful pharmaceutical, biotechnology and diagnostic companies. McLain most recently served as the General Manager, President and CEO, and Chief Operating Officer for Exosome Diagnostics, Inc., a leading developer of liquid biopsy diagnostics for use in personalised medicine. While there, McLain led the transition from a research to a commercial company and was instrument...